Natera (NASDAQ:NTRA) Price Target Raised to $190.00

Natera (NASDAQ:NTRA - Free Report) had its price objective hoisted by The Goldman Sachs Group from $160.00 to $190.00 in a research note released on Tuesday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the medical research company's stock.

NTRA has been the subject of a number of other reports. Guggenheim boosted their target price on shares of Natera from $170.00 to $200.00 and gave the company a "buy" rating in a research note on Friday, January 17th. TD Cowen boosted their price objective on shares of Natera from $155.00 to $175.00 and gave the stock a "buy" rating in a research note on Wednesday, November 13th. Craig Hallum increased their price objective on shares of Natera from $121.00 to $157.00 and gave the company a "buy" rating in a research report on Wednesday, November 13th. Piper Sandler raised their price objective on Natera from $150.00 to $200.00 and gave the stock an "overweight" rating in a research note on Monday, November 18th. Finally, Robert W. Baird upped their target price on Natera from $120.00 to $160.00 and gave the company an "outperform" rating in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat, Natera currently has an average rating of "Moderate Buy" and a consensus target price of $165.88.

Natera Price Performance

Shares of NTRA stock traded up $0.67 on Tuesday, reaching $176.94. The company's stock had a trading volume of 1,052,950 shares, compared to its average volume of 1,393,498. The stock's fifty day simple moving average is $166.70 and its 200-day simple moving average is $137.70. Natera has a 1 year low of $64.74 and a 1 year high of $183.00. The company has a market capitalization of $23.36 billion, a price-to-earnings ratio of -100.53 and a beta of 1.65. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.57) by $0.31. The business had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company's quarterly revenue was up 63.9% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.95) earnings per share. Analysts forecast that Natera will post -1.56 earnings per share for the current fiscal year.

Insider Activity at Natera

In other news, Director Gail Boxer Marcus sold 2,212 shares of the company's stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $158.53, for a total transaction of $350,668.36. Following the completion of the sale, the director now owns 19,386 shares of the company's stock, valued at $3,073,262.58. This represents a 10.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Solomon Moshkevich sold 4,858 shares of the firm's stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $166.59, for a total transaction of $809,294.22. Following the completion of the transaction, the insider now directly owns 114,912 shares in the company, valued at approximately $19,143,190.08. This represents a 4.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 243,122 shares of company stock valued at $40,336,290. 7.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Blue Trust Inc. increased its holdings in shares of Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after buying an additional 97 shares during the last quarter. Quarry LP lifted its stake in Natera by 148.4% during the 2nd quarter. Quarry LP now owns 318 shares of the medical research company's stock worth $34,000 after acquiring an additional 190 shares in the last quarter. Versant Capital Management Inc lifted its position in shares of Natera by 345.8% during the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock worth $34,000 after purchasing an additional 166 shares in the last quarter. Covestor Ltd boosted its stake in shares of Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company's stock valued at $47,000 after purchasing an additional 95 shares during the period. Finally, Principal Securities Inc. grew its holdings in shares of Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock valued at $54,000 after purchasing an additional 59 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.